Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1065)	3/28/2002 6:10:35 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 2243

6 month se profile: 89% diarrhea 21% weightloss 29% flatulence 29% headache 18% abdominal pain 4% tremor (I think this is higher in extended or high dose arm, can't recall) Only one dropped out of extended study because of diarrhea, but--and I don't mean to be unduly cynical here--that could be because cerezyme is dear. Lancet article (supposedly, I did not read) first referenced neuro side effects. GI side effects first mentioned in September in PR when 6 mos data presented at ESGLD conf. Apparently most data from low dose study is now published in Blood, Cells, Molecules and Diseases 28(2)March 2002, Heitner et al. (If you look--I did not--100 3x/day is the best starting dose.) If I heard correctly the poster at ASH merely added data on 2 patients. Company is assembling anectdotal database showing neuropathy is a disease-associated co-morbitity. They're probably right. Still, an unclean NDA. I listened to the recent presentation in website--CEO sounded like he was lacking oxygen. I could have saved some money by taking my eyes off of CNN in September and doing just a little more work on this. Loss to date is totally my fault. Could be great entry point. Wilder

To: scaram(o)uche who wrote (1065)	3/29/2002 2:08:25 PM
From: scaram(o)uche	Respond to of 2243

do hedge funds window dress? Message 17258887 Clever question. Most of us were probably watching some "tape painting" at the close yesterday. TLRK was a battle for perception not price, IMO. I think that's what it was -- tape painting -- for many of the stocks that went south. However, the question is cute..... do hedge funds put a short on the books at quarter's end, when the stock has been a good target for the quarter? Small cap biotech got the bejeezus kicked out of it this quarter. Last quarter, in a couple of days. Good riddance.